Business
Half-year Financial Report
TheraCryf plc reported a post-tax loss of £1.3 million for the six months ended 30 September 2025, an increase from £1.2 million in the prior year, with net cash outflow from operating activities at £0.7 million. The company's class-leading addiction treatment program, Ox-1, is on track for regulatory submission in Q4 2026, with manufacturing scale-up underway and a new patent granted in Korea. Cash deposits, cash, short-term investments, and equivalents stood at £3.5 million as of 30 September 2025, providing a cash runway to the end of 2026. The company also announced the appointment of Edward Wardle as a Non-Executive Director. Disclaimer*
About this update from Theracryf Plc
[{"type":"text","content":"\n\n\n \nTheraCryf plc\n \n(\"TheraCryf\" or \"the Company\" or \"the Group\")\n \nHalf Year Report to 30 September 2025\n \nClass-leading addiction programme on target to be clinic ready in 2026\n \nAlderley Park, UK, 3 December 2025. TheraCryf plc (AIM: TCF), the clinical stage drug development company focusing on brain disorders, announces its unaudited interim results for the six months ended 30 September 2025.\n \nOperational highlights\n\n· Strategic focus on Ox-11. TheraCryf's potentially class-leading addiction-treatment programme made significant progress\n\n\no Programme on track for regulatory submission in Q4 2026, enabling first-in-human studies\no Top-tier global CRO/CDMO, Pharmaron, appointed as development partner for Ox-1 after a rigorous competitive tender process.\no Manufacturing scale-up underway and on schedule, including both 0.5 kg and 10 kg batches required for regulatory submission.\no Formulation and second species selected for Ox-1 toxicology studies; two of the key milestones for clinical trial authorisation achieved\no New Ox-1 patent granted in Korea, strengthening the Company's robust global IP estate covering all major markets including Europe and the USA\n\n\n· Edward (Ed) Wardle appointed to the board as Non-Executive Director, nominated by major shareholder Northern Standard Ltd\n\n\n \nPost period\n\n\n· First 0.5 kg scale-up Ox-1 batch delivered ahead of schedule as manufacturing execution outperforms expectations.\n· Production of 2.0 kg of human-grade Ox-1 material now underway, supporting future clinical studies.\n\n\n \n\nFinancial highlights\n· Financial performance in line with expectations, with post-tax loss of £1.3m (2024: £1.2m)\n\n · Net cash outflow from operating activities before changes in working capital and tax received of £1.3m (2024: £1.2m)\n · Net cash used in operating activities £0.7m (2024: £1.4m)\n · Cash deposits, cash, short term investments and cash equivalents balance on 30 September 2025 of £3.5m (30 September 2024: £1.2m)\n\n\n· Cash runway unchanged from previous guidance to end of 2026, excluding any potential milestone payments\n\n\n&nbs...